Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase Ib Results from the JAVELIN Hodgkins Trial

Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with classical Hodgkin lymphoma (cHL), suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL.